Switzerland approves vaccine that targets two Covid variants
Moderna's new Covid-19 vaccine has been given temporary approval in Switzerland.
Copyright 2022 The Associated Press. All Rights Reserved
The Swiss medicaments regulator Swissmedic has given temporary approval for a Covid-19 vaccine from Moderna that has been adapted to give protection against two different strains of the virus.
This content was published on
1 minute
swissinfo.ch/mga
Español
es
Suiza aprueba vacuna contra dos variantes de COVID
The ‘Spikevax Bivalent Original/Omicron’ is designed to be administered in two 0.5ml doses.
It contains 25 micrograms of the original Spikevax mRNA-1273 plus 25 micrograms of a different mRNA that targets the Omicron variant (BA.1 and BA.4/5).
On Monday, Swissmedic saidExternal link that in trials the dual vaccine had achieved higher antibody concentrations against the Omicron variant than the original Spikevax, “with comparable side-effects”.
Those side-effects can include irritation, redness or swelling at the injection site, fatigue, headache, chills or nausea.
The Human Medicines Expert Committee has also given its separate seal of approval for the new vaccine, said Swissmedic.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
This content was published on
By 8am on Saturday, an 11-kilometre queue had formed at the Gotthard tunnel’s northern entrance, with drivers facing nearly two hours of delays.
Plant-based meat market in Switzerland set to grow to CHF361 million by 2030
This content was published on
Switzerland’s market for plant-based meat alternatives has a potential value of around CHF 242 million this year, though it remains a niche market.
This content was published on
The army is looking for a modern solution for its decommissioned fortress mortar bunkers, with plans to turn them into hardened defence hubs.
This content was published on
Spain ended Switzerland’s run in the Women’s Euros on Friday, but fans in Bern made history with the largest supporters’ march in Women’s Euros history.
This content was published on
Solar energy pioneer Raphaël Domjan and his team continued preparations for the altitude record attempt at 10,000 metres with the SolarStratos solar aircraft.
This content was published on
Cattle in the canton of Geneva and in the neighbouring region of Terre Sainte in the canton of Vaud are being vaccinated against the contagious viral skin nodule disease. The first cases of the animal disease were reported at the end of June in France, just outside Geneva.
Fewer attacks on Swiss ATMs but their future remains uncertain
This content was published on
Bank ATMs in Switzerland are less prone to attacks by criminals, but their future remains uncertain given the less active use of cash by the population.
This content was published on
A series of rockfalls occurred above the village of Brienz between 9 and 12 July. According to the municipality of Albula, the overall situation remains tense. Several people disregarded the ban on entering the area around the village.
This content was published on
Arosa Bergbahnen achieved the highest figure in its 95-year history in the 2024/25 financial year with net revenue of CHF 37 million. Arosa Lenzerheide was able to capitalise on strengths such as snow reliability and the size of the ski area in a long winter season, the company announced on Thursday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Switzerland gives green light to Moderna’s Covid vaccine for 6-11 year olds
This content was published on
The Swiss medical regulator Swissmedic has approved Moderna’s Spikevax Covid-19 vaccine for use by children aged 6 to 11 years.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
Too many Covid doses: Switzerland’s vaccine conundrum
This content was published on
Switzerland is sitting on around 38 million excess Covid-19 vaccine doses to be used by the end of 2022. What will it do with them?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.